Cargando…
ROS1 fusion lung adenosquamous carcinoma patient with short-term clinical benefit after crizotinib treatment: a case report
ROS1 rearrangements are validated drivers in non-small cell lung cancer (NSCLC), and occur at an extremely low rate in rare pathological subtypes such as adenosquamous carcinoma (ASC). Crizotinib is known to be effective in patients with ROS1-rearranged NSCLC. However, the efficacy of crizotinib in...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904988/ https://www.ncbi.nlm.nih.gov/pubmed/35284560 http://dx.doi.org/10.21037/atm-21-6754 |